Synopsis
Interpret calcium, phosphate and parathyroid trends as a linked CKD syndrome and prevent fractures, severe hyperparathyroidism and treatment-related calcification.
- CKD-MBD links disordered phosphate, calcium, vitamin-D and parathyroid physiology with renal osteodystrophy, fracture and vascular or soft-tissue calcification; it is more than an isolated high phosphate.
- Falling phosphate excretion and reduced calcitriol drive secondary hyperparathyroidism, initially maintaining serum calcium and phosphate at the cost of high bone turnover.
- Interpret serial calcium, phosphate, alkaline phosphatase and PTH together; a single modest PTH elevation can be adaptive and should not trigger automatic active-vitamin-D treatment.
Key red flags
Painful retiform skin lesions, livedoid change and necrosis in advanced CKD may represent calciphylaxis and require urgent renal, dermatology, wound, infection and analgesia care.
Investigation priorities
Identify hypo- or hypercalcaemia and guide vitamin-D, binder and calcimimetic safety.
Management branches
Phosphate, calcium, PTH or alkaline phosphatase changes in moderate or advanced CKD.
- Repeat and trend the linked profile, checking CKD trajectory, dialysis timing, albumin, magnesium, liver source and all binders, supplements and vitamin-D products.
- Identify modifiable phosphate intake, vitamin-D deficiency, hypocalcaemia, dialysis inadequacy, non-adherence and treatment oversuppression.
Key medicines
Calcium acetateUse the BNF meal-linked starting regimen for stage 4 or 5 CKD hyperphosphataemia and titrate to phosphate response and calcium burden.
Sevelamer carbonateUse the current SmPC meal-divided dose selected from phosphate concentration and titrate at the licensed interval under the renal formulary.